MOUNTAIN VIEW, Calif., Aug. 30, 2012 /PRNewswire/ -- A large competitor base and fluid market share has kept the research antibodies market highly competitive despite its maturity. Low entry barriers, large market size, and easy original equipment manufacturer (OEM) opportunities attract a wide variety of companies to this market. As research antibodies vary in quality by company, type, and even lot, customer satisfaction is hard to achieve. This translates to considerable chances for suppliers to capture market shares if they develop higher quality products.
New analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com) Strategic Analysis of the U.S. Research Antibodies Market research finds that the market earned revenues of $672.0 million in 2011 and estimates this to reach $775.0 million in 2016. This anticipated expansion is due to the high growth of various antibody-based technologies as well as the continued need for basic protein research.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
Many technologies and applications that require antibodies come with their own set of dynamics and growth metrics. While some of these technologies continue to grow well, others have reached maturity and are in the process of phasing out. This results in a marketplace subject to a variety of growth factors, with surges in certain hot applications and research fields.
"Researchers use antibodies in a multitude of technologies that vary by age, popularity, ease-of-use, expense, throughput, and data output," said Frost & Sullivan Senior Industry Analyst Christi Bird. "These technologies enable applications in numerous research fields, tying growth in the research antibodies market to technology and application trends within the academic research and pharmaceutical communities."
Apart from a chaotic marketplace, the economic downturn since the end of 2008 has kept growth down to the low single digits. Consequent to the slowdown, budgetary concerns and inadequate government funding of biomedical research have made researchers cautious about their spending on laboratory products. Inflation levels in biomedical research are estimated to be around 3 percent, creating greater budget constraints for researchers each year. As the research antibodies market relies heavily on the academic sector, its growth will be greatly limited for the next two years.
Growth analyses of the top competitors in the market determined that suppliers are growing at varying rates and thus, market shares are likely to change considerably over the next five years. In addition, researchers' ranking of overall experience with suppliers differs greatly from the ranking of market shares, indicating substantial prospects for reputed suppliers.
"The competitive landscape of the market is expected to be very different in the next five years, with various companies growing much faster than the overall market," said Bird. "This points to pockets of growth and opportunities for well-positioned companies to be more successful in this market, driving growth beyond the overall market compound annual growth rate of 2.9 percent between 2011 and 2016."
Strategic Analysis of the U.S. Research Antibodies Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets:
All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Strategic Analysis of the U.S. Research Antibodies Market
Corporate Communications – North America
|SOURCE Frost & Sullivan|
Copyright©2012 PR Newswire.
All rights reserved